Patents by Inventor Xiaodong Xiao

Xiaodong Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10342707
    Abstract: A wound dressing, including: a first outer layer, a second outer layer, and a middle layer disposed between the first outer layer and the second outer layer. The volume density of the first outer layer and a volume density of the second outer layer are greater than that of the middle layer; the first outer layer, the second outer layer, and the middle layer are bonded together.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: July 9, 2019
    Assignee: FOSHAN UNITED MEDICAL TECHNOLOGIES, LTD.
    Inventors: Xiaodong Wang, Xiaohui Mo, Caixia Feng, Jianpeng Xiao
  • Patent number: 10337796
    Abstract: A double-sealing type apparatus for collecting spray freeze ice ball particles and a collecting method for the double-sealing type apparatus are provided. The double-sealing type apparatus includes a collector, a collecting trolley, a vacuum pumping device, a heating device, a first sealing pad and a second sealing pad. The collector is arranged on the collecting trolley, and is provided with a collecting port. The collecting port corresponds to a discharging port at the bottom of a freezing tower. A water inlet is further provided at the collecting port, and the water inlet is in communication with a space formed by the aligning of the collecting port and the discharging port. Good sealing performance is achieved in a double-sealing manner including the sealing pads and the ice sealing, so as to smoothly transfer ice balls in the freezing tower.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 2, 2019
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Duo Wu, Zhenkai Liao, Shengyu Zhang, Zhangxiong Wu, Jie Xiao, Xiaodong Chen
  • Publication number: 20190174411
    Abstract: Provided in the present disclosure is an electronic device used for a network control terminal and a method used for the electronic device, and an electronic device used for a network node and a method used for the electronic device. The electronic device used for the network control terminal comprises: a processing circuit, configured to configure, for a relay link between the network node and one or more other network nodes, a SL-DRX for the network node and/or the one or mote other network nodes and perform relay transmission between the network node and the one or more other network nodes on the basis of the configuration of the SL-DRX.
    Type: Application
    Filed: July 21, 2017
    Publication date: June 6, 2019
    Applicant: Sony Corporation
    Inventors: Xiaodong XU, Yunqiu XIAO, Xin GUO, Shiqing ZHANG, Yi ZHANG
  • Patent number: 10306531
    Abstract: The present disclosure relates to an electronic device and a wireless communication method in a wireless communication system. The electronic device of the present disclosure comprises one or more processing circuits, configured to: acquire scenario identification information, comprising first link information that indicates the quality of a link between the electronic device and a user equipment, second link information that indicates the quality of a link between the electronic device and a base station, serving cell received power change rate information, and neighboring cell received power change rate information; and determine scenario information based on the scenario identification information, to inform the user equipment, so as to assist the user equipment to execute a relay reselection process, or to assist the electronic device to execute a relay selection process.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 28, 2019
    Assignee: SONY CORPORATION
    Inventors: Xiaodong Xu, Yi Zhang, Yunqiu Xiao, Ce Wang, Xi Ke, Bingshan Hu
  • Publication number: 20190159011
    Abstract: An electronic apparatus used on a user equipment side includes a processing circuit. The processing circuit is configured to select the mode of the relay discovery process of user equipment. In the relay discovery process, the mode determines whether the user equipment, when acting as a relay device, discovers a relayed device or is discovered by a relayed device, or whether the user equipment, when acting as a relayed device, discovers a relay device or is discovered by a relay device. After a connection is established between the relay device and the relayed device, the relayed device obtains a communication service via the relay device by means of a proximity service communication. The processing circuit is further configured to perform control, so that the user equipment carries out the relay discovery process according to the selected mode.
    Type: Application
    Filed: April 20, 2017
    Publication date: May 23, 2019
    Applicant: Sony Corporation
    Inventors: Xiaodong Xu, Yunqiu Xiao, Yi Zhang, Bingshan Hu
  • Publication number: 20190062411
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: March 29, 2018
    Publication date: February 28, 2019
    Applicant: MedImmune, LLC
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu LIN
  • Publication number: 20190040152
    Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.
    Type: Application
    Filed: July 31, 2018
    Publication date: February 7, 2019
    Inventors: Krista KINNEER, Reena VARKEY, Xiaodong XIAO, Elaine M. HURT, David TICE
  • Publication number: 20180318416
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: June 11, 2018
    Publication date: November 8, 2018
    Applicant: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Patent number: 10022443
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: July 17, 2018
    Assignee: Boston Pharmaceuticals Inc.
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20170173149
    Abstract: This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.
    Type: Application
    Filed: April 7, 2015
    Publication date: June 22, 2017
    Inventors: Catherine Ettinger, Jodi Karnell, Melissa Damschroder, Partha Chowdhury, Xiaodong Xiao, Ping Tsui, Reena Varkey, Stacey Drabic, Laura Carter, Ronald Herbst, Qun Du, Brian Michael Naiman
  • Publication number: 20170145097
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Application
    Filed: February 3, 2017
    Publication date: May 25, 2017
    Applicant: The Government of the U.S.A. as represented by the Secretary of the Dept. of Health & Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Patent number: 9598492
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: March 21, 2017
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Publication number: 20170073397
    Abstract: The present disclosure provides MrkA binding proteins, e.g., antibodies or antigen binding fragments thereof that bind to MrkA and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering MrkA binding proteins, e.g., antibodies or antigen-binding fragments thereof, MrkA polypeptides, immunogenic fragments thereof, or polynucleotides encoding MrkA or immunogenic fragments thereof to the subject.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 16, 2017
    Inventors: Qun WANG, Saravanan RAJAN, Chew-Shun CHANG, Jenny HEIDBRINK THOMPSON, Charles Kendall STOVER, Meghan PENNINI, William DALL'ACQUA, Partha S. CHOWDHURY, Xiaodong XIAO, Hung-Yu Lin
  • Publication number: 20160200832
    Abstract: This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of DPP-4 levels in samples obtained from human patients. The disclosure further provides novel anti-DPP-4 monoclonal antibodies that recognize human DPP-4, and assay kits comprising one or more of these antibodies.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: Chien-Ying Chang, Xiaodong Xiao, Partha Chowdhury
  • Publication number: 20160145338
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Application
    Filed: February 1, 2016
    Publication date: May 26, 2016
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Patent number: 9279019
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: March 8, 2016
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Patent number: 8722046
    Abstract: In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: May 13, 2014
    Assignee: The United States of America as Represented by the Secretary of the Army
    Inventors: Kei Amemiya, Dimiter S. Dimitrov, Xiaodong Xiao
  • Publication number: 20130315921
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Application
    Filed: August 5, 2013
    Publication date: November 28, 2013
    Applicant: The Government of the United States of America as represented by the Secretary of the Department of
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Patent number: 8591889
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Grant
    Filed: April 1, 2009
    Date of Patent: November 26, 2013
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • Publication number: 20120114656
    Abstract: In this application are described fully human monoclonal antibodies which specifically recognize F1 or V antigen of Y. pestis and epitopes recognized by these monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of plague infections in vitro and in vivo.
    Type: Application
    Filed: April 8, 2010
    Publication date: May 10, 2012
    Inventors: Kei Amemiya, Dimiter S. Dimitrov, Xiaodong Xiao